Satellos Bioscience (TSE:MSCL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Satellos Bioscience is launching an overnight marketed public offering of its common shares to fund the advancement of its Phase 2 clinical development and cover general corporate expenses. The offering, led by Bloom Burton Securities Inc., is set to close around December 20, 2024, pending regulatory approvals.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.